Stockreport

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MaxCyte, Inc.  (MXCT) 
PDF ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform tec [Read more]